The positive proof-of-concept data could drive near-term upside, but the small sample size and clinical hold history temper confidence. Monitor the ADA presentation on June 5 for further details and the planned Phase 2 trial initiation as key catalysts.
Price Chart
Executive Summary
Biomea Fusion reported positive 52-week Phase 2 data for icovamenib in type 1 diabetes, showing a 52% increase in C-peptide AUC at Week 12 (p<0.001) with durability through Week 52. However, the study had small sample sizes (n=5 for 200mg in early diagnosis) and was interrupted by an FDA clinical hold. The data is encouraging but early-stage, warranting cautious optimism.
Key Facts
- 52% increase in mean C-peptide AUC at Week 12 for icovamenib 200 mg in patients diagnosed within 0–3 years (n=5, p<0.001)
- Dose response observed between 200 mg and 100 mg; effect largely preserved through Week 52 (~7% decline from baseline)
- Study interrupted due to FDA clinical hold; only half of intended patient population enrolled; no placebo-controlled Part 2 completed
- Phase 2 trial with extended dosing planned for H2 2026 in collaboration with four U.S. academic centers
- Comprehensive dataset to be presented at ADA Scientific Sessions on June 5, 2026
Financial Impact
Clinical data positive for an early-stage biotech with $137M market cap; potential for significant stock movement on further data and trial initiation
Risk Factors
- Small sample sizes (n=5-6) limit statistical reliability
- FDA clinical hold interrupted enrollment; regulatory risk remains
- Larger, placebo-controlled trials may not confirm these results
- No approved therapies for beta cell preservation; high regulatory bar
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3282109 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 8-K | $0.8340 $0.6901 | ▼ −17.25% | ▼ −17.71% | $0.6360 (−23.74%) |
Oct 13, 2026 13d ago | Press Release | $0.8340 $0.6901 | ▼ −17.25% | ▼ −17.71% | $0.6360 (−23.74%) |
Sep 23, 2026 4w ago | Press Release | $1.44 $1.33 | ▼ −7.64% | ▼ −6.96% | $0.6360 (−55.83%) |
Sep 22, 2026 4w ago | 424B5 | $1.44 $1.33 | ▲ +7.64% | ▲ +6.96% | $0.6360 (+55.83%) |
Sep 22, 2026 4w ago | Press Release | $1.44 $1.33 | ▲ +7.64% | ▲ +6.96% | $0.6360 (+55.83%) |
Jun 12, 2026 19w ago | Institutional Cluster | $1.17 $1.18 | ▲ +0.85% | ▲ +0.18% | $0.6360 (−45.64%) |
Jun 5, 2026 20w ago | Press Release | $1.15 $1.20 | ▲ +4.35% | ▲ +2.24% | $0.6360 (−44.70%) |
May 11, 2026 24w ago | 8-K | $1.58 $1.25 | ▼ −20.89% | ▼ −20.96% | $0.6360 (−59.75%) |
May 11, 2026 24w ago | Press Release | $1.58 $1.25 | ▼ −20.89% | ▼ −20.96% | $0.6360 (−59.75%) |
Apr 28, 2026 25w ago | 8-K | $1.53 $1.48 | ▼ −3.27% | ▼ −4.96% | $0.6360 (−58.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers